摘要
目的探讨CD3^+CD56^+自然杀伤T细胞(natural killer T cell,NKT)及其分泌的白细胞介素(interleukin,IL)-2、IL-6、IL-10、IL-12、肿瘤坏死因子-α(tumor necrosis factor-alpha,TNF-α)等细胞因子和血清游离三碘甲状腺原氨酸(free triiodothyronine,FT_3)、游离甲状腺素(free thyroxine,FT_4)、促甲状腺激素(thyroid stimulating hormone,TSH)、甲状腺过氧化物酶抗体(thyroid peroxidase antibody,TPOAb)、甲状腺球蛋白抗体(thyroglobulin antibody,TGAb)和促甲状腺素受体抗体(thyrotrophin receptor antibody,TRAb)水平在Graves病患者体内表达情况。方法 Graves病患者30例为观察组,同期体检健康者30例为对照组,检测2组外周血CD3^+CD56^+NKT占淋巴细胞比率、CD3^+CD56^+NKT分泌的细胞因子IL-2、IL-6、IL-10、IL-12、TNF-α水平及血清FT_3、FT_4、TSH、TPOAb、TGAb、TRAb水平。结果观察组CD3^+CD56^+NKT占淋巴细胞总数比率[(1.37±0.43)%]低于对照组[(2.47±0.39)%](P<0.05);观察组血清FT_3[(23.76±5.51)pmol/L]、FT_4[(88.29±31.35)pmol/L]、TSH[(1.68±1.01)mu/L]、TPOAb[(293.58±141.32)u/mL]、TGAb[(380.58±215.31)u/mL]、TRAb抗体[(10.75±8.23)u/mL]水平均高于对照组[FT_3(4.79±0.59)pmol/L、FT_4(17.84±3.15)pmol/L、TSH(0.08±0.01)u/L、TPOAb(20.06±4.85)u/mL、TGAb(31.48±22.68)u/mL、TRAb抗体(1.21±0.23)u/mL](P<0.05);观察组血清IL-6[(2.51±0.31)μg/L]、IL-10[(43.79±21.54)ng/L]、IL-12[(1 306.14±514.39)ng/L]、TNF-α[(4.38±0.66)ng/L]水平均高于对照组[(1.01±0.20)μg/L、(27.68±5.41)ng/L、(584.34±214.57)ng/L、(2.41±0.81)ng/L](P<0.05);观察组IL-2表达水平[(1.26±0.43)ng/L]低于对照组[(4.81±0.71)ng/L](P<0.05)。结论 Graves病患者存在免疫功能紊乱情况及免疫调节细胞失衡,通过CD3^+CD56^+NKT减少及其分泌的细胞因子调节Th1/Th2分化,参与Graves病的发病过程。
Objective To investigate the expression of CD3+ CD56+ natural killer T cell (NKT), its secreted cytokines of interleukin (IL)-2, IL-6, IL-10, IL-12 and tumor necrosis factor-alpha (TNF-α), and the serum levels of free triiodothyronine (FT3), free thyroxine (FT4), thyroid stimulating hormone (TSH), thyroid peroxidase antibody (TPOAb), thyroglobulin antibody (TGAb) and thyrotrophin receptor antibody (TRAb) in patients with Graves' disease. Methods The number of CD3+ CD56+ NKT in peripheral blood, the expression levels of CD3+ CD56+ NKT secreted cytokines as IL-2, IL-6, IL-10, IL-12 and TNF-α, and the serum levels of FT3, FT4, TSH, TPOAb, TGAb and TRAb were detected in 30 patients with Graves' disease (observation group) and 30 healthy volunteers (control group). Results The proportion of CD3+ CD56+ NKT lymphocytes in total lymphocyte count was significantly lower in observation group ((1.37±0.43)%) than that in control group ((2.47±0.39)%) (P〉0.05). The serum levels of FT3((23.76±5.51) pmol/L), FT4 ((88. 29±31.35) pmol/L), TSH ((1.68±1.0]) mu/L), TPOAb ((293. 58 ±141.32) u/mL), TGAb ((380.58±215.31) u/mL) and TRAb antibody ((10.75±8.23) u/mL) in observation group were significantly higher than those in control group (FT3 : (4.79±0.59) pmol/L, FT4 : (17.84±3. 15) pmol/L, TSH: (0.08±0.01) mu/L, TPOAb: (20.06±4.85) u/mL, TGAb: (31.48±22.68) u/mL, TRAb.. (1.21±0.23) u/mL) (P〈0.05). The serum levels of IL-6 ((2.51±0.31) μg/L), IL-10 ((43.79±21.54) ng/L), IL-12 ((1 306. 14±514. 39) ng/L) and TNF-α ((4.38 ± 0. 66) ng/L) in observation group were significantly higher than those in control group (IL-6: (1. 01 ±0.20) μg/L, IL-10: (27.68±5.41) ng/L, IL-12: (584.34±214.57) ng/L, TNF-α (2.41±0.81) ng/L) (P〈0.05). The expression of IL-2 was significantly lower in observation group ((1. 26± 0. 43) ng/L) than that in control group ((4.81±0. 71) ng/L) (P〈0.05). Conclusion The patients with Graves' disease have the dysfunction of immune function and imbalance of immune-regulation ceils. The CD3+ CD56+ NKT participates the pathogenesis of Graves' disease by reducing CD3+ CD56+ NKT level and releasing different cytokines to regulate the differentiation of Thl/Th2.
出处
《中华实用诊断与治疗杂志》
2017年第1期54-56,共3页
Journal of Chinese Practical Diagnosis and Therapy
基金
2014年深圳市科技计划项目(JCYJ20140414112101551)